Icrucumab

Known as: Anti-VEGFR-1 Monoclonal Antibody IMC-18F1, Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody IMC-18F1 
A fully human IgG1 monoclonal antibody directed against human vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1) with potential… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2016
01220032016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND Icrucumab (ICR) and ramucirumab (RAM) bind vascular endothelial growth factor (VEGF) receptors 1 and 2 (VEGFR-1 and -2… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2016
2016
PURPOSE This trial assessed the efficacy and safety of docetaxel monotherapy or docetaxel in combination with ramucirumab… (More)
Is this relevant?
2016
2016
BACKGROUND Icrucumab and ramucirumab are recombinant human IgG1 monoclonal antibodies that bind VEGF receptors 1 and 2 (VEGFR-1… (More)
Is this relevant?
2013
2013
Background IMC-18F1 (icrucumab), a human monoclonal antibody against vascular endothelial growth factor receptor-1 (VEGFR-1… (More)
  • table 2
  • table 1
  • table 3
  • table 4
  • table 6
Is this relevant?
2011
2011
Recent studies suggest that chemotherapy, in addition to its cytotoxic effects on tumor cells, can induce a cascade of host… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
The Metastasis and the Tumor Microenvironment Conference, held in Philadelphia, included topics covering new research… (More)
Is this relevant?
2008
2008
Vascular endothelial growth factor receptor-1 (VEGFR-1) exists in two isoforms: a membrane-bound isoform (mVEGFR-1) and a soluble… (More)
Is this relevant?
2003
2003
OBJECTIVES The aim of this study was to investigate the prognostic value of vascular endothelial growth factor (VEGF) receptors… (More)
Is this relevant?